
Name of the Issue: Dr. Agarwal's Health Care Limited

1 Type of Issue	Initial Public Offer
2 Issue Size (Rs. Mn)	30,272.60*

*Source: Basis of Allotment

3 Grade of issue along with name of the rating agency

Name	Not Applicable
Grade	Not Applicable

4 Subscription Level (Number of times)	1.55
---	------

*The above figure is after technical rejection and excludes anchor allotment

Source: Basis of allotment

5 QIB Holding (as a % of Outstanding Capital) as disclosed to the stock exchanges

Particulars	%
(i) On Allotment *	62.07%
(iii) at the end of 1st FY (March 31, 2025)	65.83%
(iv) at the end of 2nd FY (March 31, 2026)**	N.A.
(v) at the end of 3rd FY (March 31, 2027)**	N.A.

*Shareholding pattern disclosed to Stock Exchanges

** QIB Holding not disclosed as reporting for relevant period has not been completed.

6 Financials of the issuer

(Rs. Million)

Parameters	1st FY (March 31, 2025)	2nd FY (March 31, 2026) *	3rd FY (March 31, 2027) *
Income from operations	17,110	Not Available	Not Available
Net Profit for the period	1,098	Not Available	Not Available
Paid-up equity share capital	316	Not Available	Not Available
Reserves excluding revaluation reserves	18,350	Not Available	Not Available

* Financials not available as reporting for the relevant years has not been completed.

7 Trading Status

The equity shares of the Company are listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE")
The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2026) *	Not Available
(iii) at the end of 3rd FY (March 31, 2027) *	Not Available

* Trading status not disclosed as the relevant fiscal years have not been completed.

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2025)	Not Available	Not Available
(ii) at the end of 2nd FY (March 31, 2026) *	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2027) *	Not Available	Not Available

* Changes in Directors of Issuer not updated as the relevant financial years have not been completed

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document	(i) Repayment/prepayment, in part or full, of certain of our borrowings (INR 1,950.00 mn)
	(i) Repayment/prepayment, in part or full, of certain of our borrowings (INR 1,950 mn)
(ii) Actual utilization	(ii) General corporate purposes (INR 619.07 mn)
(iii) Reasons for deviation, if any	Not Applicable

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	Not Applicable
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Not Applicable
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Not Applicable

12 Pricing Data

Designated Stock Exchange	BSE
Issue Price (Rs.)	402.00
Listing Date	4-Feb-25

Price parameters	At close of listing day- 04-Feb-25	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March, 2025)		
				Closing price	High	Low
Market Price	401.55	405.35	349.60	446.90	463.85	370.10
Sensex	78,583.81	72,989.93	80,796.84	77,414.92	85,978.25	70,234.43
Healthcare Index	42,560.75	39,701.72	42,379.81	41,421.50	43,351.09	37,778.57
Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2026)*			As at the end of the 3rd FY after the listing of the issue (31st March, 2027)*		
	Closing price	High	Low	Closing price	High	Low
Market Price	Not available*	Not available*	Not available*	Not available*	Not available*	Not available*
Sensex	Not available*	Not available*	Not available*	Not available*	Not available*	Not available*
Healthcare Index	Not available*	Not available*	Not available*	Not available*	Not available*	Not available*

* The pricing data is not disclosed as the relevant fiscal years have not been completed

13 Basis for Issue Price

Accounting ratio	As disclosed in the Prospectus	At the end of 1st FY (March 31, 2025)	At the end of 1st FY (March 31, 2026)***	At the end of 1st FY (March 31, 2027)***
EPS (Basic)	Company*	3.14	2.80	Not Available
	Peer Group & Industry Avg**		27.30	
	<i>Apollo Hospitals Enterprise Limited</i>	62.50	100.56	
	<i>Max Healthcare Institute Limited</i>	10.89	11.07	
	<i>Fortis Healthcare Limited</i>	7.93	10.26	
	<i>Global Health Limited</i>	17.80	17.92	
	<i>Narayana Hrudayalaya Limited</i>	38.86	38.86	
	<i>Krishna Institute of Medical Sciences Limited</i>	7.75	9.61	
	<i>Aster DM Healthcare Limited</i>	3.60	6.16	
	<i>Rainbow Children's Medicare Limited</i>	21.38	23.97	
EPS (Diluted)	Company*	3.13	2.78	Not Available
	Peer Group & Industry Avg**		27.28	Not Available
	<i>Apollo Hospitals Enterprise Limited</i>	62.50	100.56	
	<i>Max Healthcare Institute Limited</i>	10.84	11.01	
	<i>Fortis Healthcare Limited</i>	7.93	10.26	
	<i>Global Health Limited</i>	17.80	17.92	
	<i>Narayana Hrudayalaya Limited</i>	38.86	38.86	
	<i>Krishna Institute of Medical Sciences Limited</i>	7.75	9.61	
	<i>Aster DM Healthcare Limited</i>	3.60	6.16	
	<i>Rainbow Children's Medicare Limited</i>	21.38	23.84	
P/E	Company*	-	159.14	Not Available
	Peer Group & Industry Avg**		68.48	Not Available
	<i>Apollo Hospitals Enterprise Limited</i>	107.11	65.85	
	<i>Max Healthcare Institute Limited</i>	95.88	99.61	
	<i>Fortis Healthcare Limited</i>	82.11	68.08	
	<i>Global Health Limited</i>	57.49	66.86	
	<i>Narayana Hrudayalaya Limited</i>	33.14	43.52	
	<i>Krishna Institute of Medical Sciences Limited</i>	79.79	66.52	
	<i>Aster DM Healthcare Limited</i>	136.07	78.70	
	<i>Rainbow Children's Medicare Limited</i>	67.90	58.71	

RONW	Company*	6.21%	5.88%	Not Available	Not Available
	Peer Group & Industry Avg**		33.66%	Not Available	Not Available
	<i>Apollo Hospitals Enterprise Limited</i>	12.97%	18.25%		
	<i>Max Healthcare Institute Limited</i>	12.58%	11.42%		
	<i>Fortis Healthcare Limited</i>	7.82%	9.04%		
	<i>Global Health Limited</i>	16.46%	14.19%		
	<i>Narayana Hrudayalaya Limited</i>	27.37%	22.73%		
	<i>Krishna Institute of Medical Sciences Limited</i>	16.96%	19.30%		
	<i>Aster DM Healthcare Limited</i>	3.63%	157.69%		
	<i>Rainbow Children's Medicare Limited</i>	17.24%	16.63%		
NAV per share	Company*	50.53	59.09	Not Available	Not Available
	Peer Group & Industry Avg**		169.49	Not Available	Not Available
	<i>Apollo Hospitals Enterprise Limited</i>	481.93	571.15		
	<i>Max Healthcare Institute Limited</i>	86.54	96.50		
	<i>Fortis Healthcare Limited</i>	101.48	118.11		
	<i>Global Health Limited</i>	108.17	126.08		
	<i>Narayana Hrudayalaya Limited</i>	141.98	177.45		
	<i>Krishna Institute of Medical Sciences Limited</i>	228.47	53.43		
	<i>Aster DM Healthcare Limited</i>	71.62	68.63		
	<i>Rainbow Children's Medicare Limited</i>	124.03	144.58		

Notes

- 1 All the financial information for listed industry peers is on a consolidated basis and is sourced from the financial information of such listed industry peer as at and for the year ended
- 2 Shares outstanding are as of September 30, 2024 apart from Narayana Hrudayalaya Limited where shares outstanding are as of December 31, 2024.
- 3 Subsequent to the year ended March 31, 2024, the effect of stock split has been adjusted retrospectively presented for peers.
- 4 P/E ratio for the listed industry peers has been computed based on the closing market price of equity shares on BSE Limited ("BSE") as on January 15, 2024 divided by the diluted
- 5 Return on Net Worth (%) is calculated as profit for the year attributable to the owners of our Company divided by the Net Worth at the end of the respective year.
- 6 Net asset value (NAV) per equity share (book value per equity share) represents net worth divided by weighted average number of shares as of March 31, 2024.
- 7 Net worth means aggregate of equity share capital, instruments entirely equity in nature and other equity excluding legal reserve, capital redemption reserve and other amalgamation
- 8 In the case of Max Healthcare Institute Limited, revenue from operations includes income from other network and partner healthcare facilities, namely Balaji Society, GM Modi Society,
- 9 Basic and Diluted EPS for Aster DM are for the continuing business operations only.

14 Any other material information

Particulars	Date
Announcement under Regulation 30 (LODR)-Earnings Call Transcript	10-Feb-26
Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011	07-Feb-26
Announcement under Regulation 30 (LODR)-Investor Presentation	03-Feb-26
Announcement under Regulation 30 (LODR)-Monitoring Agency Report	03-Feb-26
Grant Of Options Under Dr. Agarwal'S Health Care Limited - Employees Stock Option Scheme 2022	03-Feb-26
Announcement under Regulation 30 (LODR)-Change in Registered Office Address	03-Feb-26
Consolidated And Standalone Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended	03-Feb-26
Board Meeting Outcome for Consolidated And Standalone Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2025 And Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015	03-Feb-26
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	12-Jan-26
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS	06-Jan-26
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	03-Jan-26
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	03-Jan-26
Shareholder Meeting / Postal Ballot-Scrutinizer's Report	19-Dec-25
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS	12-Dec-25
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	06-Dec-25
Announcement under Regulation 30 (LODR)-Newspaper Publication	18-Nov-25
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot	17-Nov-25
Change in Statutory Auditors of the Company and its Material Indian Subsidiary.	12-Nov-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	10-Nov-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome	31-Oct-25
Announcement under Regulation 30 (LODR)-Investor Presentation	31-Oct-25
Announcement under Regulation 30 (LODR)-Monitoring Agency Report	30-Oct-25
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS	30-Oct-25
Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended September 30, 2025	30-Oct-25
Board Meeting Outcome for For Approval Of Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended September 30, 2025	30-Oct-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	28-Oct-25
Board Meeting Intimation for Considering And Approving Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2025	22-Oct-25
Announcement under Regulation 30 (LODR)-Credit Rating	14-Oct-25
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015	08-Oct-25
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	03-Oct-25
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015	26-Sep-25
Closure of Trading Window	26-Sep-25
Shareholder Meeting / Postal Ballot-Scrutinizer's Report	25-Sep-25
Shareholder Meeting / Postal Ballot-Outcome of AGM	24-Sep-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	11-Sep-25
Announcement under Regulation 30 (LODR)-Newspaper Publication	03-Sep-25
Announcement under Regulation 30 (LODR)-Earnings Call Transcript	03-Sep-25
Letter Sent To Members Providing Weblink Of The Annual Report 2024-25	03-Sep-25
Reg. 34 (1) Annual Report.	02-Sep-25
Annual Report For Financial Year 2024-25 And Notice For 15Th Annual General Meeting	02-Sep-25
Annual Report For Financial Year 2024-25 And Notice For 15Th Annual General Meeting	02-Sep-25

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	28-Aug-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome	28-Aug-25
Announcement under Regulation 30 (LODR)-Investor Presentation	27-Aug-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	27-Aug-25
Announcement under Regulation 30 (LODR)-Press Release / Media Release	27-Aug-25
Board Meeting Outcome for Approval Of Matters Under Regulation 30 Of SEBI (LODR) Regulations, 2015	27-Aug-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	19-Aug-25
Announcement under Regulation 30 (LODR)-Earnings Call Transcript	16-Aug-25
Announcement under Regulation 30 (LODR)-Monitoring Agency Report	14-Aug-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome	12-Aug-25
Unaudited Financial Results For The Quarter Ended June 30, 2025	12-Aug-25
Announcement under Regulation 30 (LODR)-Investor Presentation	12-Aug-25
Board Meeting Outcome for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended	12-Aug-25
Update On Earnings Call For Quarter Ended June 30, 2025	08-Aug-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	06-Aug-25
Board Meeting Intimation for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter	30-Jul-25
Announcement under Regulation 30 (LODR)-Credit Rating	30-Jul-25
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	04-Jul-25
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	02-Jul-25
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	02-Jul-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	25-Jun-25
Closure of Trading Window	25-Jun-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	24-Jun-25
Announcement under Regulation 30 (LODR)-Earnings Call Transcript	02-Jun-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome	29-May-25
Announcement under Regulation 30 (LODR)-Investor Presentation	29-May-25
Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended March 31, 2025	28-May-25
Commencement Of Operations - New Delhi	27-May-25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	24-May-25
Compliances-Reg.24(A)-Annual Secretarial Compliance	21-May-25
Board Meeting Intimation for Approval Of Audited Financial Results (Standalone And Consolidated) For The Quarter And	20-May-25
Announcement under Regulation 30 (LODR)-Monitoring Agency Report	15-May-25
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS	14-May-25
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS	21-Apr-25
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	03-Apr-25
Commencement Of Operations Of New Branch - Eluru	27-Mar-25
Closure of Trading Window	27-Mar-25
Commencement Of Operations Of A New Branch - Udhna	24-Mar-25
Commencement Of Operations Of A New Branch - Dombivli	21-Mar-25
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015	17-Mar-25
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015	13-Mar-25
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015	13-Mar-25
Commencement Of Operations Of A New Branch - Gopalpatnam	12-Mar-25
Commencement Of Operations Of A New Branch - Karimnagar	10-Mar-25
Commencement Of Operations Of A New Branch - Virar	08-Mar-25
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011	07-Mar-25
Commencement Of Operations Of New Branches - Mysore And Siddipet	06-Mar-25
Commencement Of Operations Of A New Branch - Jaunpur	03-Mar-25

Commencement Of Operations Of A New Branch	27-Feb-25
Commencement Of Operations Of A New Branch	24-Feb-25
Commencement Of Operations Of A New Branch	21-Feb-25
Commencement Of Operation Of A New Branch	19-Feb-25
Announcement under Regulation 30 (LODR)-Credit Rating	17-Feb-25
Integrated Filing (Financial)	15-Feb-25
Outcome Of Board Meeting For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31, 2024	14-Feb-25
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011	14-Feb-25
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results	11-Feb-25
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011	07-Feb-25
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011	06-Feb-25
Listing of Equity Shares of Dr. Agarwals Health Care Ltd	04-Feb-25

Note: For further updates and information, please refer Stock Exchange websites